323105 VU Innovation & Leadership in Preclinical Drug Development - MPS5 (2024S)
Continuous assessment of course work
Labels
Registration/Deregistration
Note: The time of your registration within the registration period has no effect on the allocation of places (no first come, first served).
- Registration is open from Fr 09.02.2024 19:39 to Mo 01.04.2024 12:00
- Deregistration possible until Mo 01.04.2024 12:00
Details
Language: English
Lecturers
Classes (iCal) - next class is marked with N
Monday
04.03.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Tuesday
05.03.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Wednesday
06.03.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Monday
11.03.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Wednesday
13.03.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Monday
18.03.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Tuesday
19.03.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Tuesday
09.04.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Thursday
11.04.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Wednesday
17.04.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Thursday
18.04.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Tuesday
23.04.
16:45 - 19:15
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Thursday
25.04.
17:00 - 20:00
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Information
Aims, contents and method of the course
Assessment and permitted materials
1. Attendance & Participation: participants are expected to attend all course sessions and actively participate in the course.
2. Three team oral presentations and exercises to be handed in as outlined during the course.
3. Participants will be assessed individually on attendance, application of concepts learned in class, relevant participation in discussions, active and meaningful contribution to team assignments and exercises.
2. Three team oral presentations and exercises to be handed in as outlined during the course.
3. Participants will be assessed individually on attendance, application of concepts learned in class, relevant participation in discussions, active and meaningful contribution to team assignments and exercises.
Minimum requirements and assessment criteria
-Class attendance.
- Active participation in class and with team.
- Deliver assignments as outlined in class.
- Three (3) oral presentations (team effort).
Final Presentation (3rd)- Final evaluation. Presentation of pitch and early stage solution design concept (team effort).
- Active participation in class and with team.
- Deliver assignments as outlined in class.
- Three (3) oral presentations (team effort).
Final Presentation (3rd)- Final evaluation. Presentation of pitch and early stage solution design concept (team effort).
Examination topics
Required Final Assignment - Oral presentation with a developed story line (Pitch), and a primitive prototype design (early stage mock-up of the design concept) [team effort]. Presentation to be submitted by email (PPT, KEY or OpenOffice formats) before it is given orally. Content and requirements to be discussed in class.
Reading list
Recommended Reading (optional):
1. Ross, Alec. The Industries of the Future. Simon & Schuster, 2016.
2. Kelley, Tom. The Art of Innovation. New York: Doubleday, 2005.
3. Gallo, Carmine. The Innovation Secrets of Steve Jobs. New York: McGraw-Hill, 2011, 31.
4. Vise, David & Mark Malseed. The Google Story. New York: Dela- corte Press, 2005, 256.
5. John Battelle. The Search: How Google and Its Rivals Rewrote the Rules of Business and Transformed Our Culture. New York: Penguin Group, 2005, 141.
6. Dyer, Jeff, Hal Gregersen & Clayton M. Christiansen. The Innovator’s DNA. Boston, MA: Harvard Business School Press, 2011.
7. Christensen, Clayton M. & Michael Raynor. Innovator’s Solution. Boston, MA: Harvard Business School Press, 2003.
8. Christensen, Clayton M. The Innovator’s Dilemma: When New Technologies Cause Great Firms to Fail. Boston, MA, Harvard Business School Press, 1997.
9. Christensen, Clayton M. Meeting the Challenge of Disruptive Change. Harvard Bus. School Press, 1997.
10. “The Life and Work of Dr. Paul." https://www.janssen.com/belgium/life-and-work-dr-paul
11. Abou-Gharbia, M. & Childers, W.E. Discovery of Innovative Therapeutics: Today's Realities and Tomorrow's Vision. 1. Criticisms Faced by the Pharmaceutical Industry. J. Med. Chem. (2016):56, 5659.
12. Brown, Tim. Design Thinking. Harvard Business Review (2008), 84.
13.Elvidge, S. Footfalls & Heartbeats: Smart knitted textiles for quanti ed self and patient monitoring Start-Up, 17 December 2013. https://www.innovationintextiles.com/footfalls-heartbeats-launches-crowdfunding-campaign-to-produce-smart-knitted-fabrics/
14. Szcerba, R.J. No Donor Required: 5 Body Parts You Can Make With 3-D Printers. Forbes, 17June 2016. https://www.forbes.com/sites/robertszczerba/2015/06/17/no-donor-required-5-body-parts-you-can-make-with-3-d-printers-2/#
15. Szczerba, R.J. Why Mobile Health Technologies Haven’t Taken Off (Yet). Forbes, 16 July 2014. https://www.forbes.com/sites/robertszczerba/2014/07/16/why-mobile-health-technologies-havent-taken-off-yet/#2bfcf73076ed
1. Ross, Alec. The Industries of the Future. Simon & Schuster, 2016.
2. Kelley, Tom. The Art of Innovation. New York: Doubleday, 2005.
3. Gallo, Carmine. The Innovation Secrets of Steve Jobs. New York: McGraw-Hill, 2011, 31.
4. Vise, David & Mark Malseed. The Google Story. New York: Dela- corte Press, 2005, 256.
5. John Battelle. The Search: How Google and Its Rivals Rewrote the Rules of Business and Transformed Our Culture. New York: Penguin Group, 2005, 141.
6. Dyer, Jeff, Hal Gregersen & Clayton M. Christiansen. The Innovator’s DNA. Boston, MA: Harvard Business School Press, 2011.
7. Christensen, Clayton M. & Michael Raynor. Innovator’s Solution. Boston, MA: Harvard Business School Press, 2003.
8. Christensen, Clayton M. The Innovator’s Dilemma: When New Technologies Cause Great Firms to Fail. Boston, MA, Harvard Business School Press, 1997.
9. Christensen, Clayton M. Meeting the Challenge of Disruptive Change. Harvard Bus. School Press, 1997.
10. “The Life and Work of Dr. Paul." https://www.janssen.com/belgium/life-and-work-dr-paul
11. Abou-Gharbia, M. & Childers, W.E. Discovery of Innovative Therapeutics: Today's Realities and Tomorrow's Vision. 1. Criticisms Faced by the Pharmaceutical Industry. J. Med. Chem. (2016):56, 5659.
12. Brown, Tim. Design Thinking. Harvard Business Review (2008), 84.
13.Elvidge, S. Footfalls & Heartbeats: Smart knitted textiles for quanti ed self and patient monitoring Start-Up, 17 December 2013. https://www.innovationintextiles.com/footfalls-heartbeats-launches-crowdfunding-campaign-to-produce-smart-knitted-fabrics/
14. Szcerba, R.J. No Donor Required: 5 Body Parts You Can Make With 3-D Printers. Forbes, 17June 2016. https://www.forbes.com/sites/robertszczerba/2015/06/17/no-donor-required-5-body-parts-you-can-make-with-3-d-printers-2/#
15. Szczerba, R.J. Why Mobile Health Technologies Haven’t Taken Off (Yet). Forbes, 16 July 2014. https://www.forbes.com/sites/robertszczerba/2014/07/16/why-mobile-health-technologies-havent-taken-off-yet/#2bfcf73076ed
Association in the course directory
Last modified: Th 08.02.2024 19:46
This course is in English and fulfills 2 ECTS.
An experiential learning method allows students to apply concepts covered in class to real situations.
- Laptops, tablets, phones or other devices are allowed and encouraged in this class. These tools will enable you to search the internet and gather information for your projects and class discussion.